Revvity has acquired companies in sectors with high-growth potential, such as cell and gene therapies, and precision medicine, among other sectors. The company has strengthened its debt position, ...
When PerkinElmer’s diagnostics and life sciences businesses separated from its food safety, environmental testing and industrial quality assurance segments and rebranded as Revvity earlier this year, ...
Revvity Inc. (NYSE: RVTY) on Monday reported fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55. Adjusted operating income was $229 ...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives ...
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...
Revvity, Inc. is a major laboratory instrument and service provider to the healthcare industry. The company has historically underperformed compared to its peers in terms of profit generation and ...
Revvity, Inc. (NYSE:RVTY) is included in our list of the 14 Tech Stocks to Sell Now According to Ken Fisher. Revvity, Inc. (NYSE:RVTY) launched its new In Vivo Imaging Center of Excellence in ...
Revvity Inc. (NYSE:RVTY) stock is trading lower on Monday following the life science tools maker’s second-quarter 2025 earnings report, which also included a trimmed profit forecast for 2025. The ...
Hosted on MSN
Revvity’s (NYSE:RVTY) Q4 CY2025 sales beat estimates
Life sciences company Revvity (NYSE:RVTY) reported in Q4 CY2025, with sales up 5.8% year on year to $772.1 million. The company’s full-year revenue guidance of $2.98 billion at the midpoint came in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results